Roosevelt Investment Group Inc. trimmed its holdings in Allergan plc (NYSE:AGN) by 12.7% in the 4th quarter, HoldingsChannel reports. The fund owned 28,624 shares of the company’s stock after selling 4,179 shares during the quarter. Roosevelt Investment Group Inc.’s holdings in Allergan were worth $4,682,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Fairbanks Capital Management Inc. increased its stake in shares of Allergan by 5.7% in the 4th quarter. Fairbanks Capital Management Inc. now owns 7,003 shares of the company’s stock worth $1,146,000 after acquiring an additional 376 shares in the last quarter. Associated Banc Corp increased its stake in shares of Allergan by 11.9% in the 4th quarter. Associated Banc Corp now owns 61,094 shares of the company’s stock worth $9,994,000 after acquiring an additional 6,516 shares in the last quarter. Buckley Wealth Management LLC bought a new position in shares of Allergan in the 4th quarter worth about $317,000. NuWave Investment Management LLC bought a new position in shares of Allergan in the 4th quarter worth about $271,000. Finally, Wealthstreet Investment Advisors LLC bought a new position in shares of Allergan in the 4th quarter worth about $214,000. Institutional investors own 79.76% of the company’s stock.

Shares of Allergan plc (NYSE:AGN) opened at $162.46 on Tuesday. Allergan plc has a 1 year low of $157.70 and a 1 year high of $256.80. The company has a market cap of $54,134.55, a PE ratio of -12.11, a P/E/G ratio of 1.17 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.74 by $0.12. The firm had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.90 EPS. equities analysts predict that Allergan plc will post 15.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date of this dividend is Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is presently -20.86%.

Several research analysts recently issued reports on AGN shares. JPMorgan Chase & Co. set a $275.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Sunday, October 22nd. Cowen set a $280.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Friday, October 20th. Sanford C. Bernstein set a $252.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Wednesday, October 18th. Deutsche Bank set a $251.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Tuesday, October 17th. Finally, UBS Group set a $255.00 price objective on shares of Allergan and gave the company a “buy” rating in a research report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $227.23.

In other news, insider William Meury sold 11,807 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Roosevelt Investment Group Inc. Decreases Position in Allergan plc (AGN)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/13/roosevelt-investment-group-inc-decreases-position-in-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.